This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, J. C. Articles by O'Connell, P. Search for Related Content PubMed PubMed Citation Articles by Chang, J. C. Articles by O'Connell, P. Social Bookmarking                            What's this?

Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients

From the Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine; and the Methodist Hospital, Houston, TX

Address reprint requests to Jenny Chang, MD, Breast Center, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030; e-mail: jcchang{at}breastcenter.tmc.edu

PURPOSE: Chemotherapy for operable breast cancer decreases the risk of death. Docetaxel is one of the most active agents in breast cancer, but resistance or incomplete response is frequent.

PATIENTS AND METHODS: Core biopsies from 24 patients were obtained before treatment with neoadjuvant docetaxel (four cycles, 100 mg/m² every 3 weeks), and response was assessed after chemotherapy. After 3 months of neoadjuvant chemotherapy, surgical specimens (n = 13) were obtained, and laser capture microdissection (LCM; n = 8) was performed to enrich for tumor cells. From each core, surgical, and LCM specimen, sufficient total RNA (3 to 6 µg) was extracted for cDNA array analysis using the Affymetrix HgU95-Av2 GeneChip (Affymetrix, Santa Clara, CA).

RESULTS: From the initial core biopsies, differential patterns of expression of 92 genes correlated with docetaxel response (P = .001). However, the molecular patterns of the residual cancers after 3 months of docetaxel treatment were strikingly similar, independent of initial sensitivity or resistance. This relative genetic homogeneity after treatment was observed in both LCM and non-LCM surgical specimens. The residual tumor after treatment in tumors that were initially sensitive indicates selection of a residual and resistant subpopulation of cells. The gene expression pattern was populated by genes involved in cell cycle arrest at G₂M (eg, mitotic cyclins and cdc2) and survival pathways involving the mammalian target of rapamycin.

CONCLUSION: A specific and consistent gene expression pattern was found in residual tumors after docetaxel treatment. These profiles provide therapeutic targets that could lead to improved treatment.

Supported in part by the US Army Medical Research and Materiel Command grant No. DAMD17-01-0132, a Grant-in-Aid (US 11115) from Aventis Pharmaceutical Inc, the Emma Jacobs Clinical Breast Cancer Fund, and the Breast Cancer Specialized Program of Organized Research Excellence grant No. P50 CA50183 from the National Cancer Institute.

Presented in part at the 39th Annual American Society of Clinical Oncology Meeting, Chicago IL, May 31-June 3, 2003.

J.C.C. and E.C.W. contributed equally to this work.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. VICI, F. GIOTTA, L. DI LAURO, M. BRANDI, V. GEBBIA, P. FOGGI, V. LORUSSO, C. VITUCCI, D. SERGI, S. I. FATTORUSO, et al. Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines Anticancer Res, May 1, 2009; 29(5): 1841 - 1845. [Abstract] [Full Text] [PDF]

				V. Cappelletti, M. Gariboldi, L. De Cecco, S. Toffanin, J. F Reid, L. Lusa, E. Bajetta, L. Celio, M. Greco, A. Fabbri, et al. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer Endocr. Relat. Cancer, June 1, 2008; 15(2): 439 - 449. [Abstract] [Full Text] [PDF]

				X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy J Natl Cancer Inst, May 7, 2008; 100(9): 672 - 679. [Abstract] [Full Text] [PDF]

				J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]

				S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al. Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697. [Abstract] [Full Text] [PDF]

				M. J. C. Ellis Neoadjuvant Therapy for Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 55 - 57. [Abstract] [Full Text] [PDF]

				J. D. Minna, L. Girard, and Y. Xie Tumor mRNA Expression Profiles Predict Responses to Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4329 - 4336. [Full Text] [PDF]

				G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy J Natl Cancer Inst, May 2, 2007; 99(9): 694 - 705. [Abstract] [Full Text] [PDF]

				S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk Microarrays in breast cancer research and clinical practice - the future lies ahead Endocr. Relat. Cancer, December 1, 2006; 13(4): 1017 - 1031. [Abstract] [Full Text] [PDF]

				D. W. Lin, I. M. Coleman, S. Hawley, C. Y. Huang, R. Dumpit, D. Gifford, P. Kezele, H. Hung, B. S. Knudsen, A. R. Kristal, et al. Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis J. Clin. Oncol., August 10, 2006; 24(23): 3763 - 3770. [Abstract] [Full Text] [PDF]

				H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027. [Abstract] [Full Text] [PDF]

				J S Reis-Filho, C Westbury, and J-Y Pierga The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231. [Abstract] [Full Text] [PDF]

				J. D. Brenton, L. A. Carey, A. A. Ahmed, and C. Caldas Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application? J. Clin. Oncol., October 10, 2005; 23(29): 7350 - 7360. [Abstract] [Full Text] [PDF]